Loading...
•
Jun 30
Novartis Q2 2025 Earnings Report
Novartis reported strong Q2 2025 results with double-digit sales and net income growth.
Key Takeaways
Novartis delivered a robust Q2 2025 with $14.05 billion in revenue, driven by strong sales from Kisqali, Pluvicto, and Scemblix. Net income rose to $4.02 billion, and free cash flow increased significantly. The company raised its FY25 core operating income guidance.
Revenue grew to $14.05 billion, driven by key growth brands
Net income increased to $4.02 billion, supported by strong operating performance
Core EPS reached $2.42, reflecting improved margins
FY25 core operating income guidance raised to low-teens growth
Novartis
Novartis
Novartis Revenue by Segment
Revenue by Segment
Entresto Revenue
CapyFin.comCosentyx Revenue
CapyFin.comKisqali Revenue
CapyFin.comKesimpta Revenue
CapyFin.comPluvicto Revenue
CapyFin.comScemblix Revenue
CapyFin.comLeqvio Revenue
CapyFin.com Forward Guidance
Novartis expects high single-digit sales growth and low-teens core operating income growth for FY25.
Positive Outlook
- Raised FY25 core operating income guidance to low-teens growth
- Strong momentum in key growth brands Kisqali, Pluvicto, and Scemblix
- Positive Phase III readout for Pluvicto in hormone-sensitive prostate cancer
- Initiation of up to $10 billion share buyback by year-end 2027
- Robust free cash flow supporting capital allocation flexibility
Challenges Ahead
- Entresto faces potential US generic entry mid-2025
- Higher investments behind priority brands may pressure margins
- Net debt increased to $23.8 billion due to buybacks and M&A
- Exposure to currency fluctuations impacting core operating income
- Ongoing IP and regulatory litigation for key products